ischemic heart disease
Conditions
Interventions
None listed
Sponsors
department of cadiovascular medicine, Chiba university graduate school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion criteria included the following: patients undergoing elective PCI; patients keeping taking aspirin; patients agreeing with this study after informed consent.
Exclusion criteria
Exclusion criteria: The exclusion criteria included the following: patients with unstable hemodynamics; patients underwent PCI or CABG within 4 weeks; patients in whom prasugrel is contraindicated; patients with severe hepatic dysfunction(liver cirrhosis, fulminant hepatitis, AST >100IU/L, ALT >100IU/L or Total bilirubin >3.0mg/dL); patients with severe renal dysfunction(eGFR <30mL/min); patients <50kg; patients with thorombocytepenia(platelet cell <100000/microL); patients with pregnancy or suspected pregnancy; patients administrated with anticoagulants(warfarin, dabigatran, rivaroxaban, apixaban or edoxaban); patients undergoing thrombolytic therapy; patinets administrated ticlopidine, cilostazol or clopidogrel; patients added or changed the drug for hypertension, dyslipidemia, diabetes or hyperuricemia within 2 weeks before agreement with this study; patients judged not eligible in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reactive hyperemia index on 24 hours and 28 days after taking prasugrel compared with it on baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| P2Y12 reaction units on 23 hours and 28 days after taking prasugrel compared with it on baseline | — |
Countries
Japan
Contacts
Public ContactSatoshi Tokimasa
Chiba university graduate school of medicine department of cardiovascular medicine
Outcome results
None listed